PRESS RELEASES

Ergomed expands operations in Japan

RNS
PRESS RELEASE

Ergomed expands operations in Japan

New legal entity and regional office established in Tokyo responding to client demand

Guildford, UK 26 April 2021: Ergomed plc (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, announces that its PrimeVigilance business, a global leader in the provision of pharmacovigilance and medical information services, has established its new legal entity and regional office in Japan and is fully operational from 26 April 2021.

The new subsidiary company, trading as PrimeVigilance Japan KK, is based in Tokyo and offers a comprehensive range of pharmacovigilance services, including a dedicated Japanese safety database. Full Japanese language Medical Information services are also provided.

This expansion provides existing and prospective international PrimeVigilance clients the opportunity to extend their product coverage into the strategically important Japanese pharmaceutical market, the fourth largest globally after the US, the EU and China. It also provides PrimeVigilance and Ergomed the opportunity to provide high quality specialist services to domestic Japanese companies, opening up a new market.

PrimeVigilance has a strong operational presence in Europe and the recent acquisitions of Ashfield PV and MedSource, as well as significant organic growth in the US, have elevated PrimeVigilance into a market leading position in North America. The new facility in Japan adds Asia to Ergomed’s global footprint, enabling PrimeVigilance to offer operational services in all major regions, with pharmacovigilance and medical information professionals based in each territory, providing both local and global expertise.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: Ergomed has provided a breadth of services and expertise in Asia both as a CRO and as a pharmacovigilance specialist through its outsourcing model for many years. With a solid base of international clients in Japan, Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategically important Asia region. Following the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource, this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services specialist.”

Enquiries:

Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Matthew O’Dowd (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal [email protected]
Olivia Manser / Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

Latest News

Philips introduces integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3 to improve workflow and patient focus during image-guided procedures at ACC.21

May 14, 2021 Continuous monitoring provides informed, timely clinical decision making and comprehensive, gap-free patient records in the cath lab and beyond Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the integration of its Interventional Hemodynamic System and market-leading portable Patient Monitor IntelliVue X3, providing […]

PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma

Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act. RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma®, PRA’s proprietary technology that […]

Align Technology Supports the United Kingdom’s General Dental Council (GDC) Statement on Direct-to-Consumer Orthodontics which Highlights Patient Safety Issues

Updated GDC Policy Statement Affirms Requirement and Importance of a Physical Examination for Orthodontic Treatment and for Patients to Know the Full Name of the Dental Professional Responsible for their Orthodontic Treatment BIRMINGHAM, United Kingdom and TEMPE, Ariz., May 13, 2021 (GLOBE NEWSWIRE) — Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company […]

Constellation Brands Invests in Disruptive Rosé Brand Geared Toward Multicultural Consumers in La Fête Du Rosé

Investment marks first as part of Constellation’s Focus on Minority Founders initiative and commitment to invest $100 million in Black/minority-owned businesses by 2030 La Fête du Rosé Founder Donae Burston Created a Brand to Serve Millennial and Gen Z, Focused on Shared Values, Taste, and Experiences VICTOR, N.Y., May 13, 2021 (GLOBE NEWSWIRE) — Constellation […]